

New Drugs to Be Added to NHI Price List on May 20, 2020

Brand name	Specification	Company	Generic name	NHI price (yen)	Pricing method	Premium, etc.	Indication
Latuda Tablets 20 mg 40 mg 60 mg 80 mg	20 mg/tablet 40 mg/tablet 60 mg/tablet 80 mg/tablet	Sumitomo Dainippon	lurasidone HCl	178.70 328.90 469.90 493.40	Comparator method (II)		Schizophrenia and depressive symptoms in bipolar disorder (NME)
Melatobel Granules 0.2% for Pediatric	0.2%/g	Nobelpharma	melatonin	207.80	Comparator method (I)	Premium for usefulness (II) (5%) Premium for pediatric use (10%) Eligible for PMP*	Improvement of sleep onset difficulties associated with neurodevelopmental disease in children (NME)
Lokelma for Oral Suspension 5 g 10 g	5 g/sachet 10 g/sachet	AZ	sodium zirconium cyclosilicate hydrate	1,095.20 1,601.00	Comparator method (I)	Upward adjustment based on average foreign price	Hyperkalemia (NME)
Cabpirin Combination Tablet	1 tablet	Takeda	aspirin + vonoprazan fumarate	130.30	Special pricing rule for combination drugs		Prevention of blood clot and thrombus formations in the following patients (only those with a history of gastric or duodenal ulcer): 1) Patients with angina (chronic stable angina, unstable angina), myocardial infarction, and ischemic cerebrovascular disorder, (transient ischemic attack, cerebral infarction) 2) Patients who have undergone coronary artery bypass grafting or percutaneous transluminal coronary angioplasty (New combination drug)
Cabometyx Tablets 20 mg 60 mg	20 mg/tablet 60 mg/tablet	Takeda	cabozantinib malate	8,007.60 22,333.00	Comparator method (I)	Premium for usefulness (II) (10%) Eligible for PMP* Subject to CEA (H1 product)	Unresectable/metastatic renal cell carcinoma (NME)
Tepmetko Tablets 250 mg	250 mg/tablet	Merck Biopharma	tepotinib HCl hydrate	14,399.00	Comparator method (I)	Premium for usefulness (II) (5%) <i>Sakigake</i> premium (10%) Eligible for PMP*	MET exon 14 skipping mutation-positive unresectable advanced/recurrent non-small cell lung cancer (NME)
Velexbru Tablet 80 mg	80 mg/tablet	Ono	tirabrutinib HCl	5,067.40	Comparator method (I)	Eligible for PMP*	Recurrent/refractory primary central nervous system lymphoma (NME)
Anerem IV Injection 50 mg	50 mg/vial	Mundipharma	remimazolam besilate	2,218	Cost-based method		Induction and maintenance of general anesthesia (NME)
Beovu kit for intravitreal injection 120 mg/mL	6 mg/0.05 mL/syringe	Novartis	brolocizumab (recombinant)	142,784	Comparator method (I)		Age-related macular degeneration with subfoveal choroidal neovascularization (NME)
Viltepso Injection 250 mg	250 mg/5 mL/vial	Nippon Shinyaku	viltolarsen	91,136	Cost-based method	Premium for marketability (I) (10%) <i>Sakigake</i> premium (10%) Eligible for PMP*	Duchenne muscular dystrophy with confirmed loss of the dystrophin gene that can be treated with exon 53 skipping therapy (NME)
Ozempic SC Injection 0.25 mg SD 0.5 mg SD 1.0 mg SD	0.25 mg/0.5 mL/kit 0.5 mg/0.5 mL/kit 1 mg/0.5 mL/kit	Novo Nordisk	semaglutide (recombinant)	1,547 3,094 6,188	Comparator method (II)		Type 2 diabetes (NME)
Lyumjev Injection Cart Miriopen Miriopen HD 100 Units/mL	300 units/syringe 300 units/kit 300 units/kit 100 units/1 mL/vial	Eli Lilly	insulin lispro (recombinant)	1,175 1,400 1,400 277	Same as existing products		Insulin therapy-indicated diabetes (New formulation)
Soliqua Injection SoloStar	1 kit	Sanofi	insulin glargine (recombinant) + lixisenatide	6,497	Special pricing rule for combination drugs		Insulin therapy-indicated type 2 diabetes (New combination drug)
Onivyde IV Infusion 43 mg	43 mg/10 mL/vial	Nihon Servier	irinotecan HCl hydrate	128,131	Cost-based method	Premium for usefulness (II) (10%) Upward adjustment based on average foreign price Eligible for PMP*	Unresectable pancreatic cancer that has progressed following chemotherapy (New indication/formulation)
Enhertu for IV Drip Infusion 100 mg	100 mL/vial	Daiichi Sankyo	trastuzumab deruxtecan (recombinant)	165,074	Comparator method (I)	Premium for usefulness (II) (5%) Eligible for PMP* Subject to CEA (H1 product)	HER2-positive inoperable/relapsed breast cancer after prior chemotherapy (only in patients who are refractory or intolerant to standard treatments) (NME)
Steboronine IV Drip Bag 9000 mg/300 mL	9,000 mg/300 mL/bag	Stella Pharma	borofalan (10B)	444,215	Cost-based method	Premium for usefulness (I) (35%) <i>Sakigake</i> premium (10%) Eligible for PMP*	Unresectable locally advanced/locally recurrent head and neck cancer (NME)
Vonvendi IV 1300	1,300 IU/vial (with solvent)	Shire	vonicog alfa (recombinant)	146,288	Cost-based method	Premium for usefulness (II) (5%) Premium for marketability (I) (10%) Eligible for PMP*	Controlling bleeding tendency in patients with von Willebrand disease (NME)
Ailamide Combination Ophthalmic Suspension	1 mL	Senju	brimonidine tartrate + brinzolamide	492.20	Special pricing rule for combination drugs		Glaucoma and ocular hypertension inadequately controlled with other existing glaucoma treatments (New combination drug)

*PMP: Price maintenance premium